Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2006-04-04
2006-04-04
Housel, James C. (Department: 1648)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S130100, C424S133100, C424S143100, C530S387100, C530S387300, C530S388100, C530S388220
Reexamination Certificate
active
07022323
ABSTRACT:
This invention provides a method of inhibiting HCV infection of a cell susceptible to HCV infection which comprises contacting the cell with an amount of a compound effective to inhibit binding of an HCV envelope glycoprotein to a DC-SIGN protein present on the surface of the cell, so as to thereby inhibit HCV infection of the cell susceptible to HCV infection. This invention provides a method of inhibiting HCV infection of a cell susceptible to HCV infection which comprises contacting the cell with an amount of a compound effective to inhibit binding of an HCV envelope glycoprotein to a DC-SIGNR protein present on the surface of the cell, so as to thereby inhibit HCV infection of the cell susceptible to HCV infection. Compounds of the present invention inhibit HCV infection of cells susceptible to HCV infection. The compounds of the present invention preferably have specificity for preventing or inhibiting infection by HCV and do not inhibit infection by other viruses, such as HIV, that may utilize DC-SIGN or DC-SIGNR for infection. Moreover the compounds of the present invention preferably do not interfere or inhibit members of the immunoglobulin superfamily, in particular, the compounds do not interfere with ICAM-2 or ICAM-3 or with ICAM-2-ilke, or ICAM-3-like molecules.
REFERENCES:
patent: 5595868 (1997-01-01), Habets et al.
patent: 5679342 (1997-10-01), Houghton et al.
patent: 6391567 (2002-05-01), Littman et al.
patent: 1046651 (2000-10-01), None
patent: 9208734 (1992-05-01), None
patent: 0063251 (2000-10-01), None
patent: 0250119 (2002-06-01), None
patent: 03000024 (2003-01-01), None
Rudikoff et al., Proceedings of the National Academy of Sciences, USA, vol. 79, pp. 1979-1983 (Mar. 1982).
Poljak et al., Philosophical Transactions of the Royal Society of London, Series B: Biological Sciences, vol. 272, pp. 43-51 (Nov. 1975).
Bartosch et al, Journal of Biological Chemistry, vol. 278 No. 43, pp. 41624-41630 (Oct. 2003).
Daugherty et al., Nucleic Acids Research, vol. 19 No. 9, pp. 2471-2476 (May 1991).
Walker et al., Antiviral Chemistry & Chemotherapy, vol. 14 No. 1, pp. 1-21 (Jan. 2003).
U.S. Appl. No. 60/300,971, filed Jun. 26, 2001, Olson et al.
U.S. Appl. No. 09/891,894, filed Jun. 26, 2001, Olson et al.
U.S. Appl. No. 10/328,997, filed Dec. 24, 2002, Olson et al.
Mitchell, D.A., Fadden, A.J. and Drickamer, K. (2001) A novel mechanism of carbohydrate recognition by the C-type lectins DC-SIGN and DC-SIGNR. Subunit organization and binding to multivalent ligands. J. Biol. Chem. 276: 28939-28945.
Geijtenbeek, T.B.H. et al. (2000) Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary immune responses. Cell 100: 575-585.
Nguyen, D.G. and Hildreth, J.E.K. (2003) Involvement of macrophage mannose receptor in the binding and transmission of HIV by macrophages. European Journal of Immunology 33:483-493; and.
Pohlmann, S. et al. (2003) Hepatitis C virus glycoproteins interact with DC-SIGN and DC-SIGNR. Journal of Virology 77: 4070-4080.
Auffermann-Gretzinger, S., E.B. Keeffe, and S. Levy. 2001. Impaired dendritic cell maturation in patients with chronic, but not resolved, hepatitis C virus infection. Blood 97: 3171-3176.
Bain, C., A. Fatmi, F. Zoulim, J.P. Zarski, C. Trepo, and G. Inchauspe. 2001. Impaired allostimulatory function of dendritic cells in chronic hepatitis C infection. Gastroenterology 120: 512-524.
Baribaud, F., S. Pohlmann, T. Sparwasser, M.T. Kimata, Y.K. Choi, et al. 2001. Functional and antigenic characterization of human, rhesus macaque, pigtailed macaque, and murine DC-SIGN. J. Virol. 75: 10281-10289.
Bashirova, A.A., T.B. Geijtenbeek, G.C. van Duijnhoven, S.J. van Vliet, J.B. Eilering, et al. 2001. A dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin (dc-sign)-related protein is highly expressed on human liver sinusoidal endothelial cells and promotes HIV-1 infection. J. Exp. Med. 193: 671-678.
Carloni, G., S. Iacovacci, M. Sargiacomo, G. Ravagnan, A. Ponzetto, C. Peschle, and M. Battaglia. 1993. Suspectibility of human liver cell cultures to hepatitis C virus infection. Arch. Virol. Suppl. 8:31-39.
Cocquerel, L., C. Wychowski, F. Minner, F. Penin, and J. Dubuisson. 2000. Charged residues in the transmembrane domains of hepatitis C virus glycoproteins play a major role in the processing, subcellular localization, and assembly of these envelope proteins. J. Virol. 74: 3623-3633.
Cocquerel, L., J.C. Meunier, A. Pillez, C. Wychowski, and J. Dubuisson. 1998. A retention signal necessary and sufficient for endoplasmic reticulum localization maps to the transmembrane domain of hepatitis C virus glycoprotein E2. J. Virol. 72: 2183-2191.
Cocquerel, L., S. Duvet, J.C. Meunier, A. Pillez, R. Cacan, C. Wychowski, and J. Dubuisson. 1999. The transmembrane domain of hepatitis C virus glycoprotein E1 is a signal for static retention in the endoplasmic reticulum. J. Virol. 73: 2641-2649.
Deleersnyder, V., A. Pillez, C. Wychowski, K. Blight, J. Xu, Y.S. Hahn, C.M. Rice, and J. Dubuisson. 1997. Formation of native hepatitis C virus glycoprotein complexes. J. Virol. 71: 697-704.
Dubisson, J. 2000. Folding, assembly and subcellular localization of hepatitis C virus glycoproteins. Curr. Top. Microbiol. Immunol. 242: 135-148.
Flint M, and J.A. McKeating. 2000. The role of the hepatitis C virus glycoproteins in infection. Rev. Med. Virol. 10: 101-117.
Flint, M., J. Dubuisson, C. Maidens, R. Harrop, G.R. Guile, P. Borrow, and J.A. McKeating. 2000. Functional characterization of intracellular and secreted forms of a truncated hepatitis C virus E2 glycoprotein. J. Virol. 74: 702-709.
Flint, M., J.M. Thomas, C.M. Maidens, C. Shotton, S. Levy, W.S. Barclay, and J.A. McKeating. 1999. Functional analysis of cell surface-expressed hapatitis C virus E2 glycoprotein. J. Virol. 73: 6782-6790.
Geijtenbeek, T.B., D.S. Kwon, R. Torensma, S.J. van Vliet, G.C. van Duijnhoven, J. Middel, J.L. Cornelissen, H.S. Nottet, V.N. KewalRamani, D.R. Littman, C.G. Figdor, and Y. van Kooyk. 2000. DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell 100: 587-597.
Geijtenbeek, T.B., Y. van Kooyk, S.J. van Vliet, M.H. Renes, R.A. Raymakers, and C.G. Figdor. 1999. High frequency of adhesion defects in B-lineage acute lymphoblastic leukemia. Blood 94: 754-764.
Iacovacci, S., L. Bertolini, A. Manzin, M.B. Valli, M. Battaglia, A. Ponzetto, M. Clementi, and G. Carloni. 1997. Quantitation of hepatitis C virus RNA production in two human bone marrow-derived B-cell lines infected in vitro. Res. Virol. 148: 147-151.
Jameson, B., F. Baribaud, S. Pohlmann, D. Ghavimi, F. Mortari, R.W. Doms, and A. Iwasaki. 2002 Expression of DC-SIGN by dendritic cells of intestinal and genital mucosae in humans and rhesus macaques. J. Virol. 76: 1866-1875.
Jones, I.M., C. Chan-Fook, W.R. Jiang, and B.E. Clarke. 2000. Receptors for hepatitis C virus. J. Virol. 74: 10860-10861.
Kanto, T., N. Hayashi, T. Takehara, T. Tatsumi, N. Kuzushita, A. Ito, Y. Sasaki, A. Kasahara, and M. Hori. 1999. Impaired allostimulatory capacity of peripheral blood dendritic cells recovered from hepatitis C virus-infected inviduals, J. Immunol. 162: 5584-5591.
Lagging, L.M., K. Meyer, R.J. Owens, and R. Ray. 1998. Functional role of hepatitis C virus chimeric glycoproteins in the infectivity of pseudotyped virus. J. Virol. 72: 3539-3546.
Lanford, R.E., C. Sureau, J.R. Jacob, R. White, and T.R. Fuerst. 1994. Demonstration of in vitro infection of chimpanzee hepatocytes with hepatitis C virus using strand-specific RT/PCR. Virology 202: 606-614.
Lohmann, V., F. Korner, J. Koch, U. Herian, L. Theilmann, and R. Bartenschlager. 1999. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285: 110-113.
Matsuura, Y., T. Suzuki, R. Suzuki, M. Sato, H. Aizaki, I. Saito, and T. Miyamura. 1994. Processing of E1 and E2 glycoproteins of hepatitis C virus expressed in mammalian and insect cells. Virology 205: 141-150.
Mellor, J., G. Haydon, C. Blair, W. Livingstone, and P. Simmonds. 1998. Low level or absent in vivo replicati
Maddon Paul J.
Olson William C.
Cooper & Dunham LLP
Housel James C.
Lucas Zachariah
Progenics Pharmaceuticals Inc.
White, Esq. John P.
LandOfFree
Uses of DC-SIGN and DC-SIGNR for inhibiting hepatitis C... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Uses of DC-SIGN and DC-SIGNR for inhibiting hepatitis C..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Uses of DC-SIGN and DC-SIGNR for inhibiting hepatitis C... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3570193